Abstract: A compound specified by formula (I), in particular dimethylfumarate (trans-1,2-ethylenedicarboxylic acid dimethyl ester) is provided for use in prevention or therapy of gout, acne, pyoderma gangrenosum, Vitiligo, cardiovascular disease, metabolic syndrome, diabetes and/or complications of diabetes. Also provided are a dosage form comprising said compound and a method of treatment comprising administration of said compound to a patient in need thereof.

Abstract: A band-pass filter is described comprising a first first-order filter stage comprising a first resistor characterised by a first impedance and connected to a first node, referred to as a filter input node, and, through a second node to a first reactive component connected to a third node, the first impedance being such that a first current therethrough is dependent on the difference between the voltages at the first and second nodes; and a second first-order filter stage comprising a second resistor characterised by a second impedance and connected to the second node, and, through a fourth node, to a second reactive component connected to a fifth node. The second impedance is such that a second current therethrough is dependent on the negative of the sum of the voltages at the second and fourth nodes. The band-pass filter further comprises summing means for summing the voltages at the second and fourth nodes to output a voltage at a sixth node.

Abstract: The invention relates to a combination medicament comprising a human interleukin-2 (hIL-2)-specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25, and an immune checkpoint inhibitor agent. The hIL-2 antibody can be given without or with recombinant hIL-2 and is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.

Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Abstract: A magnetic field probe, particularly for magnetic resonance applications, comprises: —a detector liquid that exhibits a nuclear magnetic resonance (NMR) line characterized by a chemical shift ?; —an electrically conductive structure surrounding the detector liquid for receiving therefrom a magnetic resonance signal; and —a container containing the detector liquid; —the detector liquid containing paramagnetic dopant means dissolved therein; —said NMR transition having an observable resonance frequency ? when the field probe is placed in an external magnetic field; and has orientation means for orienting the field probe in relation to a reference direction of said external magnetic field.

Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.

Abstract: A magnetic resonance (MR) system comprises a main magnetic field and an RF power amplifier for generating an RF field in a first RF band, the arrangement further comprising at least one magnetic field probe (2), said magnetic field probe comprising a MR active probe substance, means for pulsed MR excitation of said probe substance (4) in a second RF band and means for receiving a probe MR signal in the second RF band generated by said probe substance. In order to improve performance of the system, the latter comprises means for recording the output signal of the RF power amplifier in said second RF band, and means for subtracting from said probe MR signal an interfering signal contribution contained in said recorded RF amplifier output signal.

Abstract: The invention relates to a bispecific HER2-targeting agent comprising a.) a first polypeptide ligand that binds to HER2 extracellular domain 1, b.) a second polypeptide ligand that binds to HER2 extracellular domain 4 and c.) a linker covalently attaching said first polypeptide ligand to said second polypeptide ligand.

Abstract: The invention relates to a method for diagnosis of colorectal carcinoma in a patient, including detecting, in a blood sample obtained from said patient, an indicator protein selected from integrin subunit alpha(v) and integrin subunit beta(6) or their heterodimer.

Abstract: The invention relates to a system and a method for tracking position and orientation of an object in a magnetic resonance (MR) apparatus.

Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention and treatment of allergic disorders, in particular atopic asthma. More particularly, the invention relates to tolerogenic agents and compositions thereof that are useful for the prevention and treatment of hypersensitivity to allergens, in particular strategies of desensitization to allergens.

Abstract: A device including a cochlear implant electrode array and an apparatus configured to sense a phenomenon of fluid in a cochlea, wherein the apparatus and the electrode array are a single unit.

Abstract: The invention relates to a sleeve (1) for providing a dental implant (2) with a disinfectable surface (100b), wherein the sleeve (1) is configured to be attached to an end or coronal region (20) of a dental implant (2), wherein the sleeve (1) comprises a through hole (101) encompassed by the sleeve (2) which through hole (101) is adapted to receive said end region (20) of the dental implant (2), wherein said through hole (101) is delimited by an inside (100a) of the sleeve which faces said through hole (101), and wherein the sleeve (1) comprises an outside (100b) facing away from said inside (100a), which outside (100b) forms said disinfectable or sterilizable surface (100b). Further, the invention relates to an arrangement of the sleeve on a dental implant as well as to a method for arranging the sleeve on a dental implant.

Abstract: A method of determining an actual gradient impulse response function during execution of a magnetic resonance (MR) imaging or spectroscopy sequence, wherein a main magnetic field is generated in a sample region of an MR apparatus by means of a main magnet and wherein superimposed time dependent gradient fields and radiofrequency fields in a first RF band are generated in the sample region according to a first MR sequence for forming images or spectra, the gradient fields being generated by gradient forming means of the MR apparatus operated according to a gradient forming sequence part of said first MR sequence, the MR apparatus further comprising at least one magnetic field probe.

Abstract: In a method for determining charge and/or size of an object (15) suspended in a fluid, the object (15) is introduced, together with the fluid, into an electrostatic trap (1) defining an electrostatic confining potential. The thermal motion of the object (15) in the fluid is observed under influence of the confining potential, and charge and/or size are determined from the observed thermal motion. In particular, the viscous drag on the object yields a measure of its size, while the stiffness of its confinement can be compared with a potential model to reveal the total charge it carries. Also disclosed are an apparatus and software for carrying out the method.

Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.

Abstract: The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline. Such synthetic virus-like particles carrying proline-rich antigens derived from pneumococcal proteins are useful as vaccines against infectious diseases caused by Gram-positive bacteria such as Streptococcus pneumoniae.

Abstract: A method of determining the position of at least one magnetic field probe located within a pre-defined volume of interest within a magnetic resonance (MR) imaging or spectroscopy arrangement comprises applying a spatially and temporally variable magnetic reference field having a unique time-course at every point in said volume of interest during a preselected time window. An MR signal is ac-quired from said magnetic field probe during said time window, and the position of the probe is determined from the probe MR signal.

Abstract: The invention relates to antibodies reactive to acetylated PCSK9, particularly to PCSK9 acetylated in position Lys421, Lys273, Lys69, Lys83, Lys243, Lys258, Lys494, and/or Lys506, and related reagents. The invention also relates to a method of reducing LDL-cholesterol level in a patient in need thereof, said method comprising administering to the subject an effective amount of an antibody binding to acetylated PCSK9. The invention also relates to a method of treating a cholesterol related disorder in a patient in need thereof, said method comprising administering to the subject an effective amount of an antibody binding to acetylated PCSK9. The invention also relates to a method of treating hypercholesterolemia in a patient in need thereof, said method comprising administering to the subject an effective amount of an antibody binding to acetylated PCSK9.

Abstract: The invention relates to an apparatus (1) for unloading a user's body weight during a physical activity of said user (4), particularly for gait training of said user (4), comprising: a plurality of ropes (41, 42, 43, 44), wherein each rope (41, 42, 43, 44) extends from an associated drive unit (510, 520, 530, 540), is deflected by a passively displaceable deflection device, e.g.